
The Scottish Medicines Consortium (SMC) has enabled access to Kyowa Kirin’s Crysvita (burosumab) for the NHS in Scotland to treat …

NICE has announced its evidence-based recommendation that Kyowa Kirin International’s Crysvita (burosumab) be made available on the NHS for the …
Five Facts about cardiovascular disease
Artificial hearts: a century of innovation

